Antineoplastic Agents: Clinical Trials

13 trials of Antineoplastic Agents, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 unknown, 2 completed, 2 terminated. 13 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Recruiting 4, Unknown 3, Completed 2, Terminated 2, Not yet recruiting 1, Suspended 1
Phase 14Completed 1, Recruiting 1, Terminated 1, Unknown 1
Phase 31Recruiting 1

Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).
RAG-01, Chemotherapy agent - Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 2Not yet recruitingRactigen Therapeutics.1142026-09-012026-09-15
Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Low Dose Radiotherapy Combined with Tislelizumab and Chemotherapy, Chemotherapeutic Agent, low-dose radiotherapy - Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2RecruitingJiangsu Cancer Institute & Hospital1142026-05-142026-11-06
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
Sintilimab, Chemotherapy Drugs, radiotherapy - Rectal Cancer
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital1302026-05-012026-05-19
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
Carrelizumab, Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin - Non Small Cell Lung Cancer
Phase 2UnknownUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology302021-08-202021-09-02
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs - Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
Phase 2 / Phase 3RecruitingARCAGY/ GINECO GROUP1382020-07-152026-09-09
A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients
Plasma soluble TNF receptor pulldown, Plasma soluble TNF receptor pulldown + chemotherapy, Chemotherapy Drugs, Cancer - Advanced Breast Cancer
Phase 1 / Phase 2UnknownImmunicom Inc1702019-05-312022-03-24
Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
Chemotherapy Drugs, Cancer - Metastatic Breast Cancer
Phase 1 / Phase 2RecruitingShaare Zedek Medical Center152019-04-182020-10-23
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
Bevacizumab - Advanced Ovarian Cancer
Phase 2UnknownNada Hassan Salah402018-09-012018-08-02
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Oshadi D & Oshadi R;, salvage therapy cytosar and mitoxantrone - Acute Myeloid Leukemia, Lymphoid Leukemia
Phase 2SuspendedOshadi Drug Administration152017-01-012018-04-18
Chemoembolization for Hepatocellular Carcinoma
TACE, Cisplatin - Hepatocellular Carcinoma
Phase 2TerminatedChinese University of Hong Kong242012-02-012017-08-22
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
Idarubicin, Cytarabine, Lenalidomide (Revlimid®) - Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase 1 / Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute512009-06-252020-12-22
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
Paclitaxel, Drug: Ad.p53-DC vaccines, All -trans Retinoic Acid (ATRA) - Small Cell Lung Cancer
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute692007-10-022019-11-08
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
ABT-751, Dexamethasone, PEG-asparaginase - Recurrent Pediatric ALL, Relapsed Pediatric ALL
Phase 1 / Phase 2TerminatedTherapeutic Advances in Childhood Leukemia Consortium92006-05-222021-03-17

Conditions studied

Breast Neoplasms (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Leukemia, Lymphoid (1)  ·  Leukemia, Monocytic, Acute (1)  ·  Myelodysplastic Syndromes (1)  ·  Non-Muscle Invasive Bladder Neoplasms (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Rectal Neoplasms (1)  ·  Recurrence (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

H. Lee Moffitt Cancer Center and Research Institute (2)  ·  ARCAGY/ GINECO GROUP (1)  ·  Chinese University of Hong Kong (1)  ·  Immunicom Inc (1)  ·  Jiangsu Cancer Institute & Hospital (1)  ·  Nada Hassan Salah (1)  ·  Oshadi Drug Administration (1)  ·  Ractigen Therapeutics. (1)  ·  Shaare Zedek Medical Center (1)  ·  Therapeutic Advances in Childhood Leukemia Consortium (1)  ·  Tianjin Medical University Cancer Institute and Hospital (1)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)

Countries

China (4)  ·  United States (3)  ·  France (1)  ·  Hong Kong (1)  ·  Israel (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)

Top investigators

Adam Ostrowski, MD (1)  ·  Alberto A Gabizon, MD, PhD (1)  ·  Dingwei Ye (1)  ·  Gang Li, PhD. MD. (1)  ·  Jeffrey Lancet, M.D. (1)  ·  Moshe Gatt, MD (1)  ·  Paul S Gaynon, MD (1)  ·  Scott Antonia, M.D. (1)  ·  Simon Yu (1)  ·  Yongde Liao, PhD (1)

Results publications

PMID 14998846, PMID 25415656, PMID 26408258, PMID 27912846, PMID 42361329